NCT07272356Active, not recruiting
Evaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing Function
Investigation of the Efficacy of Local Minimally Invasive Ablative Therapy for Pulmonary Tumors and Its Impact on Respiratory Function
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
This clinical study is evaluating different treatment options for patients with malignant lung tumors, including both primary lung cancer and tumors that have spread to the lungs from other parts of the body. The goal is to compare the safety, effectiveness, and quality-of-life impact of three approaches: surgery, stereotactic body radiotherapy (SBRT), and minimally invasive thermal ablation (microwave or cryoablation). Thermal ablation is a procedure in which a small antenna is inserted through the skin into the tumor and the cancer cells are destroyed using heat or freezing. SBRT uses precisely targeted radiation to destroy tumors, while surgery involves removing part of the lung. These methods are already used in routine care, but this study directly compares them to understand which patients may benefit most from each approach. In addition to cancer control, the study is measuring how these treatments affect breathing function. Patients will have regular follow-up visits with CT scans, breathing tests, and blood draws for up to two years. About 100 adults in Lithuania are expected to participate. The results will help doctors make better treatment recommendations, balancing cancer control with patient well-being, lung function, and quality of life.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 68 (actual)
- First submitted
- 28 Sept 2025
- Start date
- 22 Nov 2022
- Primary completion date
- 14 Jun 2026
- Lead sponsor
- Aurimas Macionis
- Diseases
- Lung cancer
- NCT number
- NCT07272356
What you commit to
- Study type: Interventional
- Participants enrolled: 68
- From 22 Nov 2022 to the primary completion date, 14 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \>5 or diffuse lung lesions, or prior local treatment to the same lesion;
- Contraindications to general anesthesia, inability to temporarily withdraw antiplatelet therapy, or evidence of severe coagulopathy.
Other
- Central lung tumors (\<2 cm from the main bronchi or hilum);
- Major comorbidities, physical or social limitations precluding trial participation;
Who the study is looking for
- Adults (18 years or older)
- Verified systemic therapy-naive biopsy-proven NSCLC, stages from Tis to T2; or oligometastatic peripheral (≤ 5 lesions) lung disease;
- All lesions are ≤3 cm in size and accessible for surgery, ablation or SBRT;
- No local nodal or distant metastatic disease on diagnostic imaging;
- Documented agreement on the recommended curative treatment by a multidisciplinary team, including a pulmonologist, interventional radiologist, radiation therapist, thoracic surgeon, and oncologist;
- Documented patient's agreement to receive the intended therapy and to participate in this study via a signed informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lithuanian University of Health Sciences Kaunas Clinics Coordinator of this site? Confirm its status | Kaunas | Lithuania | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.